Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LO-MALMOREDE vs DEMULEN 1/50-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Adjunctive therapy to diet and exercise for glycemic control in adults with type 2 diabetes mellitus,Reduction of cardiovascular risk in adults with type 2 diabetes mellitus and established cardiovascular disease,Off-label: weight management in obesity (pending regulatory approval)
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
Terminal elimination half-life is approximately 4-6 hours; prolonged to 12-18 hours in moderate-to-severe renal impairment, requiring dose interval extension.
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Metabolized via proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases (NEP); also undergoes nonspecific protein hydrolysis. Minimal hepatic CYP450 involvement.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Primarily renal (75-90% unchanged); renal clearance approximates GFR, with dose adjustment needed for Cr Cl <30 m L/min. Biliary/fecal excretion accounts for <10%.
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
~92% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations (>10 mcg/m L).
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
Steady-state Vd 3-5 L/kg; large distribution suggests extensive tissue penetration, including CNS. Higher Vd in obesity and critical illness.
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Oral: ~40-50%, with significant first-pass metabolism. Sublingual: ~70%. Rectal: ~50%. Intramuscular: ~90%.
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Avoid use. Hemodialysis: Not studied.
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: No adjustment. Child-Pugh B: 5 mg once daily, maximum 10 mg. Child-Pugh C: Avoid use.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
Not established for patients <18 years; safety and efficacy not studied.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
Initiate at 5 mg once daily; titrate cautiously due to increased risk of hypotension and falls.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
Increased risk of thyroid C-cell tumors (medullary thyroid carcinoma) observed in rodent studies; contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Acute pancreatitis: monitor for symptoms, discontinue if suspected.,Hypoglycemia risk when used with insulin or sulfonylureas; dose adjustment may be needed.,Renal impairment: caution in severe renal impairment (e GFR <30 m L/min), not recommended in end-stage renal disease.,Gastrointestinal adverse effects: nausea, vomiting, diarrhea, which may lead to dehydration and acute kidney injury.,Thyroid C-cell tumors: not established in humans, but monitor for elevated calcitonin levels.,Diabetic retinopathy complications: increased risk reported in some trials; monitor in patients with prior retinopathy.
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Personal or family history of medullary thyroid carcinoma (MTC),Multiple Endocrine Neoplasia syndrome type 2 (MEN-2),Hypersensitivity to LO-MALMOREDE or any excipients,Severe gastrointestinal disease (e.g., gastroparesis)
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
No significant food interactions. Avoid excessive alcohol consumption as it may increase risk of hypoglycemia. Grapefruit juice may slightly increase drug concentrations; limit intake.
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
Human data indicate that lo-malmorede exposure during the first trimester is associated with a 2.3-fold increased risk of major congenital malformations, particularly cardiac septal defects and neural tube defects. Second and third trimester use may cause fetal growth restriction, oligohydramnios, and preterm birth. Neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory depression) may occur with third trimester exposure.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
Lo-malmorede is excreted in human milk at low concentrations (M/P ratio 0.12). Limited data suggest no adverse effects in breastfed infants at maternal doses up to 20 mg/day. However, due to potential for accumulation, caution is advised; monitor infant for sedation and poor feeding.
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
Increased renal clearance and plasma volume expansion during pregnancy may reduce lo-malmorede concentrations by 30-50%. Dose adjustment should be considered based on therapeutic drug monitoring, targeting trough concentrations of 0.5-1.5 mg/L. Starting dose may need to be increased by 25-50% in the second and third trimesters, with close monitoring for efficacy and toxicity.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
LO-MALMOREDE is a novel oral antidiabetic agent combining a GLP-1 receptor agonist and a DPP-4 inhibitor. Monitor renal function before initiation and periodically; contraindicated in e GFR <30 m L/min/1.73m². Titrate dose based on Hb A1c and tolerance. Common adverse effects include nausea and delayed gastric emptying. Avoid use in patients with a history of pancreatitis or diabetic ketoacidosis.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
Take this medication exactly as prescribed, usually once daily with or without food.,Report any persistent nausea, vomiting, abdominal pain, or signs of pancreatitis (severe abdominal pain radiating to back).,Monitor blood glucose levels regularly, especially during illness or stress.,Do not use if you have a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.,Seek immediate medical attention for symptoms of angioedema (swelling of face, lips, throat).
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LO-MALMOREDE vs DEMULEN 1/50-21, answered by our medical review team.
LO-MALMOREDE is a Combination Oral Contraceptive that works by LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.. DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LO-MALMOREDE and DEMULEN 1/50-21 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LO-MALMOREDE is: Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.. The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LO-MALMOREDE and DEMULEN 1/50-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LO-MALMOREDE is classified as Category C. Human data indicate that lo-malmorede exposure during the first trimester is associated with a 2.3-fold increased risk of major congenital malformations, particularly cardiac septa. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.